PLENARY SPEAKER

 Pat Walters, PhD

Chief Data Officer @ Relay Therapeutics

Challenges and Opportunities for AI in ADME Modeling

 PLENARY SPEAKER

 Parag Mallick, PhD

Founder & Chief Scientist at Nautilus Biotechnology, Associate Professor @ Stanford University

The Role of Single-Cell and Single-Molecule Proteomics in Therapeutic Development

 PLENARY SPEAKER

 Malaz Abutarif, PhD

Vice President of Quantitative Clinical Pharmacology @ Daiichi Sankyo

Clinical Pharmacology of ADCs: Critical Bioanalytical Role

PLENARY SPEAKER

 Steven J Swanson, PhD, FAAPS

Senior Principal Scientist, Bioanalytical Sciences @ Genentech, Inc.

Immunogenicity Prediction - How Does This Fit in Drug Development

Brian Booth, PhD

Director DCP I, OCP, CDER, U.S. Food and Drug Administration

State of the FDA - Overview of Recent Guidances 

Salaheldin Hamed, PhD

Division of Cancer Pharmacology, OCP, CDER, U.S Food and Drug Adminstration

State of the FDA - Antibody Drug Conjugates

  Amanda Hays, PhD

Scientific Officer @ BioAgilytix

Recommendations for Development and Validation of qPCR Assays for Regulated Bioanalysis

 Jeffrey Kurz, PhD

Associate Director @ Alnylam Pharmaceuticals

Intrathecal Delivery of siRna-Conjugates to the CNS: Challenges of ADME Characterization

  Stephen Fowler, PhD

Clinical Pharmacologist @ F. Hoffmann La-Roche Ltd

MPS for ADME Applications: Moving from Aspiration to Exploration

Andy Pike, PhD

Senior DMPK Lead @ AstraZeneca 

Optimising Proteolysis Targeting Chimeras (PROTAC's) for Oral Drug Delivery: A drug metabolism and pharmacokinetics perspective

  Heather Myler, PhD

Executive Director Scientific Affairs, Analytical Sciences Division @ PPD

Supply Chain Impact on Drug Development: A Pandemic-driven Global Perspective

Christine Callahan, MS

Vice President Supply Chain, Life Sciences Solutions @ Thermo Fisher Scientific

Enhancement of Capacity and Supply Chain Capabilities - Title TBA

  Pallavi Lonkar, PhD

Senior Director, Head of Bioanalytical, DMPK and Biomarkers @ PepGen

 The Promise of Peptide-Oligonucleotide Conjugates for Neuromuscular Diseases

Shelia Breidinger, PhD

Director, Regulated Bioanalytical Outsourcing, Merck & Co, Inc.

Preclinical Bioanalytical Challenges in Supporting the COVID-19 Oral Antiviral, Molnupiravir, during a Pandemic

Yue-Ting Wang, PhD

Principal Reserarch Scientist, DMPK-BA @ AbbVie

To Infinity and Beyond Rule of Five Compounds: Challenges & Considerations for Discovery Stage Bioanalytical Support

Weixun Wang, PhD

Group Leader Discovery Bioanalysis, Merck & Co, Inc.

Development of a Target Engagement (TE) Assay for the Oral Peptide PCSK9-LDLr Inhibitor Program

Jacques Saarbach, PhD

Post-doctoral Fellow, Crews Lab, MCDB, Yale University

Expanding the Protein Degradation Toolbox

Nanda Balasubramanian, PhD

Senior Principal Scientist, Nonclinical Disposition and Bioanalysis, Bristol Myers Squibb

Bioanalytical Strategies and Challenges for CAR-T Support

Michael Swanson, PhD

Associate Scientific Director @ The Janssen Pharmaceutical Compaies of Johnson & Johnson

Bioanalytical Considerations for Assessing Immunogenicity of Cellular Therapy Products

Tomomi Kiyota, PhD

Principal Scientist @ Genentech

Renal Proximal Tubule-on-a-Chip: Performance, Utility, and Benefits for Drug Development

Jason DelCarpini, PhD

Associate Director, Quantitative Bioanalytics @ Moderna

Practical Considerations for Neutralizing Antibody Assay Development

Michele Gunsior, PhD

Senior Director @ Astria Therapeutics

Recommendations for Harmonization of Anti-Drug Antibody Sample Testing and Reporting

  Aaron Cooper, PhD

Senior Director of Synthetic Biology @ Arsenal Bio

 Programming T Cell Therapies for Solid Tumors is Enabled by Precise Delivery of Large and Modular Gene Circuits With Multiple Therapeutic Functions

Haihong Shi, PhD

Director @ Pfizer

Application of Micro-Sampling Device, Taso M20 in Pfizer's COVID-19 Therapeutics Drug PAXLOVID Development

 Kenneth Swart, PhD

SVP Bioanalytical and Biotherapeutic Sciences, Inotiv

Bioanalytical, Biotherapeutic, and Biomarker Analysis in Drug Development - Challenges and Solutions

 Hisao Shimizu, PhD

Principal Scientist DMPK @ Takeda Pharmaceutical Company

Bioanalytical Approach for Diverse Oligonucleotides Therapeutics Using Multiple BA Platforms

Gregory Walker, PhD

Associate Research Fellow @ Pfizer

The Crucial Role of NMR in Understanding the Human Disposition of PAXLOVID 

David Stresser, PhD

Senior Principal Scientist @ AbbVie

IQ Microphysiological Systems Affiliate: Accelerating the development and adoption of MPS models in industry

Douglas Spracklin, PhD

Director, Biotransformation & Environmental Sciences @ Pfizer

The AMS-enabled Human Absorption, Distribution, Metabolism & Excretion (hADME) Study: A Technological and Strategic Paradigm Shift

 Laixin Wang, PhD

Co-Founder & Senior VP @ Chongqing Denali Medpharma & Helens Clinical Research Center

Hyphenated Liquid Chromatography Techniques and qPCR: Overcoming the Bioanalytical Challenges of Oligonucleotide Therapeutics and mRNA Vaccines

Donglu Zhang, PhD

Staff Scientist @ Genentech

The Importance of Tracking "Missing" Metabolites - How and Why?"

 Yongjun Xue, PhD

Scientific Director, Nonclinical Disposition and Bioanalysis @ Bristol-Myers Squibb

Use of 1β-Hydroxydeoxycholic Acid as a Potential Biomarker for Assessment of CYP3A DDI Activity